ChemoCentryx Priced, Nasdaq: CCXI
Developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo.
Industry: Health Care
First Day Return: +10.0%
Industry: Health Care
CCXI
Developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo.
| IPO Data | |
|---|---|
| IPO File Date | 10/14/2011 |
| Offer Price | $10.00 |
| Price Range $14.00 - $16.00 | |
| Offer Shares (mm) | 4.5 |
| Deal Size ($mm) | $45 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 02/08/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $45 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Mountain View, CA, United States |
| Founded | 1997 |
| Employees at IPO | 64 |
| Website www.chemocentryx.com | |
IPO News for ChemoCentryx
ChemoCentryx (CCXI) Performance
